A detailed history of Nebula Research & Development LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Nebula Research & Development LLC holds 6,727 shares of CRNX stock, worth $360,567. This represents 0.04% of its overall portfolio holdings.

Number of Shares
6,727
Holding current value
$360,567
% of portfolio
0.04%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$43.83 - $54.98 $294,844 - $369,850
6,727 New
6,727 $344 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.88B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Nebula Research & Development LLC Portfolio

Follow Nebula Research & Development LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nebula Research & Development LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nebula Research & Development LLC with notifications on news.